Patent Law Weblog
recent posts
- Moderna Settles Patent Litigation with Arbutus et al.
- USPTO and DOJ Statement of Interest in Collision Communications: Another Thumb on the Scale in Favor of NPE Patent Plaintiffs
- Oasis Tooling, Inc. v. Siemens Industry Software Inc. (Fed. Cir. 2026)
- Why AI Will Not Take Over the World
- BioNTech Sues Moderna over mRNA Vaccine Technology
about
Category: Biotech/Pharma News
-
By Kevin E. Noonan — The U.S. Patent and Trademark Office rendered its final decision on Monday in one of the re-examinations of the Thomson stem cell patents provoked by two groups: the Public Patent Foundation (PUBPAT), headed by Dan Ravicher, and The Foundation for Taxpayer and Consumer Rights (FTCR), a California taxpayer…
-
By Kevin E. Noonan — It has been a difficult year for Genentech with regard to its blockbuster anticancer drug, Avastin® (bevacizumab). For much of the year, the company was embroiled in a dispute with the ophthalmological community over its decision (now altered) to limit sale of Avastin® for reformulation in treating age-related…
-
By Donald Zuhn — Earlier today, Patent Docs participated in a conference call with Jim Greenwood (at right), the President and CEO of the Biotechnology Industry Organization (BIO). Mr. Greenwood, who represented Pennsylvania’s Eighth District in the U.S. House of Representatives from January 1993 through January 2005 prior to his BIO appointment, had…
-
By Kevin E. Noonan — Earlier today, Patent Docs participated in a conference call with Jim Greenwood (at right), the President and CEO of the Biotechnology Industry Organization (BIO). Mr. Greenwood, who represented Pennsylvania’s Eighth District in the U.S. House of Representatives from January 1993 through January 2005 prior to his BIO appointment,…
-
By Donald Zuhn — Insmed Inc., a biopharmaceutical company based in Richmond, VA, announced last week that it was launching a campaign on the importance of establishing a regulatory pathway in the U.S. for follow-on biologics (sometimes referred to as biosimilars or biogenerics). Last summer, we reported that the U.S. Senate Committee on…
-
By Kevin E. Noonan — John White (at right) of the PLI Patent Blog came to visit some of the Patent Docs today, and he had more to say about the summary judgment hearing in Tafas/GSK v. Dudas held last Friday in the Eastern District of Virginia before Judge James C. Cacheris. Readers…
-
By Donald Zuhn — Last week, Swiss drug maker Novartis AG agree to supply its cancer drug Glivec® at no cost to patients in Thailand in exchange for the Thai government’s agreement not to issue a compulsory license on Novartis’ patent. Glivec® (imatinib), which is sold as Gleevac® (imatinib mesylate) in the U.S.,…
-
By Kevin E. Noonan — Craig Venter’s colleagues at the J. Craig Venter Institute show no signs that vocal criticism of their work in synthetic biology has made a dent in their determination to "create life" (see "Playing the Bioterror Card in the Synthetic Biology Debate"). They report in this week’s Science Express…
-
By Kevin E. Noonan — In the 19th Century, biology was an observational, rather than an experimental, science. Without an understanding of genetics, and with evolution by natural selection being but newly proposed (and in the absence of genetics, not yet accepted), biologists (natural historians, really) spent their time expanding Linnaean systematics, cataloging…
-
By Donald Zuhn — It is natural at this time of year to reflect upon the events of the past twelve months in the hope that such a review might provide some indication of what to expect in the coming year. In order to help focus on possible developments in biotech and pharma…
Patent Docs 